115 related articles for article (PubMed ID: 1727923)
1. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma.
Weber JS; Yang JC; Topalian SL; Schwartzentruber DJ; White DE; Rosenberg SA
J Clin Oncol; 1992 Jan; 10(1):33-40. PubMed ID: 1727923
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.
Margolin KA; Aronson FR; Sznol M; Atkins MB; Ciobanu N; Fisher RI; Weiss GR; Doroshow JH; Bar MH; Hawkins MJ
J Immunother (1991); 1991 Jun; 10(3):214-20. PubMed ID: 1868045
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 lymphokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease.
Bernstein ZP; Vaickus L; Friedman N; Goldrosen MH; Watanabe H; Rahman R; Arbuck SG; Sweeney J; Vesper D; Henderson ED
J Immunother (1991); 1991 Apr; 10(2):141-6. PubMed ID: 2043594
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
[TBL] [Abstract][Full Text] [Related]
6. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
Rosenberg SA; Lotze MT; Yang JC; Topalian SL; Chang AE; Schwartzentruber DJ; Aebersold P; Leitman S; Linehan WM; Seipp CA
J Natl Cancer Inst; 1993 Apr; 85(8):622-32. PubMed ID: 8468720
[TBL] [Abstract][Full Text] [Related]
7. Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.
Sparano JA; Fisher RI; Weiss GR; Margolin K; Aronson FR; Hawkins MJ; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):216-23. PubMed ID: 7834121
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 therapy with or without lymphokine-activated killer-cell infusions for low-grade non-Hodgkin's lymphomas?
Levy R; Tourani JM; Andrieu JM
J Clin Oncol; 1992 Aug; 10(8):1366. PubMed ID: 1634929
[No Abstract] [Full Text] [Related]
9. [Lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) therapy that improved lymphadenopathy in a patient with B cell non-Hodgkin's lymphoma].
Nakata K; Ogawa R; Wake A; Sato T; Nagata K; Mori N; Tsukada J; Misago M; Zeki K; Morimoto I
Rinsho Ketsueki; 1992 Feb; 33(2):205-10. PubMed ID: 1635170
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
11. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
Parkinson DR; Fisher RI; Rayner AA; Paietta E; Margolin KA; Weiss GR; Mier JW; Sznol M; Gaynor ER; Bar MH
J Clin Oncol; 1990 Oct; 8(10):1630-6. PubMed ID: 2213100
[TBL] [Abstract][Full Text] [Related]
12. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
Thompson JA; Bianco JA; Benyunes MC; Neubauer MA; Slattery JT; Fefer A
Cancer Res; 1994 Jul; 54(13):3436-41. PubMed ID: 8012963
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.
Benyunes MC; Massumoto C; York A; Higuchi CM; Buckner CD; Thompson JA; Petersen FB; Fefer A
Bone Marrow Transplant; 1993 Aug; 12(2):159-63. PubMed ID: 8401364
[TBL] [Abstract][Full Text] [Related]
14. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
Law TM; Motzer RJ; Mazumdar M; Sell KW; Walther PJ; O'Connell M; Khan A; Vlamis V; Vogelzang NJ; Bajorin DF
Cancer; 1995 Sep; 76(5):824-32. PubMed ID: 8625186
[TBL] [Abstract][Full Text] [Related]
15. A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma.
Hawkins MJ; Atkins MB; Dutcher JP; Fisher RI; Weiss GR; Margolin KA; Rayner AA; Sznol M; Parkinson DR; Paietta E
J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):74-8. PubMed ID: 8110733
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B.
Duggan DB; Santarelli MT; Zamkoff K; Lichtman S; Ellerton J; Cooper R; Poiesz B; Anderson JR; Bloomfield CD; Peterson BA
J Immunother (1991); 1992 Aug; 12(2):115-22. PubMed ID: 1504052
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
18. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
[TBL] [Abstract][Full Text] [Related]
19. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
20. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]